启迪药业(000590) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥60,492,169, a decrease of 31.16% compared to ¥87,878,389.50 in the same period last year[7]. - Net profit attributable to shareholders was ¥8,881,121.45, down 17.68% from ¥10,787,950.32 year-on-year[7]. - The company reported a significant decrease in operating costs by 40.41%, amounting to a reduction of ¥17,634,041.48 due to lower revenue[14]. - Basic and diluted earnings per share for Q1 2020 were CNY 0.0371, down from CNY 0.0450 in the previous period[38]. - The company reported a net profit of -196,821.37 yuan for Q1 2020, compared to a profit of 2,223,754.74 yuan in the same period last year[41]. - Operating profit for the quarter was -276,821.37 yuan, while the previous year showed an operating profit of 2,211,846.74 yuan[41]. - The company reported a total comprehensive income of -196,821.37 yuan for the quarter, compared to 2,223,754.74 yuan in the previous year[42]. Cash Flow - The net cash flow from operating activities improved significantly, reaching ¥1,998,622.54, a 138.59% increase compared to a negative cash flow of ¥5,179,641.84 in the previous year[7]. - Cash flow from operating activities generated a net inflow of 1,998,622.54 yuan, a significant improvement from a net outflow of -5,179,641.84 yuan in the prior year[45]. - Cash outflows related to operating activities totaled 76,440,766.65 yuan, compared to 78,107,328.58 yuan in the prior year[45]. - The company’s cash flow from financing activities resulted in a net outflow of -8,433,016.66 yuan, reflecting repayments of debts and interest payments[46]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥841,742,306.28, a slight decrease of 0.59% from ¥846,744,431.69 at the end of the previous year[7]. - The company's total liabilities decreased from ¥224,583,363.65 to ¥210,700,116.79 during the same period[29]. - The cash and cash equivalents decreased from ¥314,336,897.47 to ¥302,349,518.25[27]. - Accounts receivable decreased from ¥110,470,895.64 to ¥101,144,058.39, reflecting a decline of approximately 8.5%[27]. - The company's inventory increased from ¥50,882,354.51 to ¥55,551,754.68, representing an increase of about 9.5%[27]. - The company's total equity increased from ¥622,161,068.04 to ¥631,042,189.49, showing a growth of approximately 1.4%[30]. - Total assets as of the end of Q1 2020 were CNY 662,224,521.25, a slight decrease from CNY 667,407,941.36 at the end of the previous period[33]. - Total liabilities at the end of Q1 2020 were CNY 136,546,768.32, compared to CNY 141,533,367.06 in the previous period[33]. - Owner's equity totaled CNY 525,677,752.93 at the end of Q1 2020, slightly down from CNY 525,874,574.30 in the previous period[33]. Research and Development - Research and development expenses decreased by 33.83%, totaling a reduction of ¥949,214.18, attributed to lower personnel and investment in R&D[14]. - Research and development expenses for Q1 2020 were CNY 1,856,578.02, down from CNY 2,805,792.20 in the previous period[36]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,032, with the largest shareholder holding 29.41% of the shares[10]. - The company reported no overdue commitments from shareholders or related parties during the reporting period[22]. Government Subsidies and Investments - The company received government subsidies amounting to ¥668,261.09 during the reporting period, contributing to its non-recurring gains[8]. - The company experienced a net cash outflow from investing activities of ¥11,916,892.36, a 575.94% increase due to increased project investments[14]. - The company invested 13,986,001.76 yuan in investment activities, significantly higher than 2,069,109.40 yuan in the same period last year[45]. - The company has committed ¥16,150,000 in bank wealth management products sourced from idle raised funds[19]. Miscellaneous - The company has not engaged in any securities investments during the reporting period[17]. - The company has not reported any derivative investments during the reporting period[19]. - The company has not undergone an audit for the first quarter report of 2020[55]. - The company implemented new revenue and lease standards starting in 2020, with no retrospective adjustments applicable[55].